Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced the nationwide commercial launch of Zesuning (injectable human thyrotropin β), the first approved recombinant human thyrotropin injection in China for differentiated thyroid cancer (DTC) follow-up after total/near-total thyroidectomy. The first batch shipment completion marks the in-market debut of Zelgen’s proprietary IP asset, which eliminates the need for thyroid hormone withdrawal during postoperative assessment, improving patient compliance and quality of life while maintaining 93.6% diagnostic concordance with traditional methods.
Commercial Launch Milestone
Element
Detail
Product
Zesuning (recombinant human thyrotropin β injection)
Developer
Suzhou Zelgen Biopharmaceuticals (SHA: 688266) – independently developed; proprietary IP
~200,000 annual thyroid cancer diagnoses; 90%+ are DTC; rising incidence with improved detection
Follow-Up Standard
Thyroid hormone withdrawal (3-4 weeks) causes severe hypothyroidism; patient non-compliance common
Global Precedent
Thyrogen (rhTSH, Genzyme/Sanofi) approved U.S./EU since 1990s; Zesuning first China domestic equivalent
Pricing Power
Premium positioning vs. withdrawal method; NRDL inclusion critical for access
Diagnostic-therapeutic Integration
Enables accurate ¹³¹I therapy planning without treatment delays
Competitive Dynamics
Product
Developer
Status
Zesuning Differentiation
Thyrogen (rhTSH)
Genzyme/Sanofi
Approved (U.S., EU, limited China access)
First China-developed rhTSH; domestic manufacturing cost advantage
Thyroid Hormone Withdrawal
—
Standard of care (free)
Eliminates hypothyroidism burden; superior patient experience
Zesuning
Zelgen
Launched (March 2026)
China proprietary IP; Merck commercialization; 93.6% concordance
Forward-Looking Priorities
2026 Launch Execution: Hospital endocrinology/oncology department penetration; nuclear medicine center partnerships
NRDL Negotiation: 2026-2027 national reimbursement list inclusion for volume scaling
Merck Integration: Sales force training; co-promotion with Merck’s diabetes/endocrinology portfolio
Global Expansion: U.S./EU IND preparation; potential for 505(b)(2) pathway leveraging China data
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch performance, reimbursement negotiations, and global expansion for Zesuning. Actual results may differ due to competitive dynamics with Thyrogen, pricing regulations, and diagnostic practice pattern adoption.-Fineline Info & Tech
By Fineline Cube 